Sumitomo Pharma Future Growth
Future criteria checks 0/6
Sumitomo Pharma's earnings are forecast to decline at 7.9% per annum while its annual revenue is expected to grow at 5.8% per year. EPS is expected to decline by 10.7% per annum. Return on equity is forecast to be 13.4% in 3 years.
Key information
-7.9%
Earnings growth rate
-10.74%
EPS growth rate
| Pharmaceuticals earnings growth | 13.0% |
| Revenue growth rate | 5.8% |
| Future return on equity | 13.43% |
| Analyst coverage | Good |
| Last updated | 11 Sep 2026 |
Recent future growth updates
Recent updates
Narrative Update • Sep 03
4506: Index Inclusion And Leukemia Pipeline Will Support Future Upside
Analysts now place Sumitomo Pharma's fair value at approximately ¥2,071, up from ¥2,000. The updated target reflects revised assumptions for the discount rate, revenue growth, profit margin and future P/E.Analysis Article • Aug 09
Sumitomo Pharma's (TSE:4506) Attractive Earnings Are Not All Good News For Shareholders
We didn't see Sumitomo Pharma Co., Ltd.'s ( TSE:4506 ) stock surge when it reported robust earnings recently. We looked...Narrative Update • Jul 31
4506: Orphan Drug Designations Will Support Future Leukemia Pipeline Upside
Analysts now place Sumitomo Pharma's fair value estimate at ¥2,000, down from ¥2,158. The adjustment reflects updated views on revenue growth, profit margins, and the appropriate discount rate and P/E multiple for the stock.Analysis Article • Feb 06
Investors Shouldn't Be Too Comfortable With Sumitomo Pharma's (TSE:4506) Earnings
Sumitomo Pharma Co., Ltd.'s ( TSE:4506 ) robust earnings report didn't manage to move the market for its stock. Our...Analysis Article • Jan 10
Optimistic Investors Push Sumitomo Pharma Co., Ltd. (TSE:4506) Shares Up 26% But Growth Is Lacking
Despite an already strong run, Sumitomo Pharma Co., Ltd. ( TSE:4506 ) shares have been powering on, with a gain of 26...Analysis Article • Jan 02
Is Sumitomo Pharma (TSE:4506) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Nov 13
Investors Appear Satisfied With Sumitomo Pharma Co., Ltd.'s (TSE:4506) Prospects As Shares Rocket 38%
Despite an already strong run, Sumitomo Pharma Co., Ltd. ( TSE:4506 ) shares have been powering on, with a gain of 38...Analysis Article • Aug 04
Results: Sumitomo Pharma Co., Ltd. Beat Earnings Expectations And Analysts Now Have New Forecasts
A week ago, Sumitomo Pharma Co., Ltd. ( TSE:4506 ) came out with a strong set of first-quarter numbers that could...Analysis Article • Jul 30
Sumitomo Pharma Co., Ltd.'s (TSE:4506) Shares Climb 36% But Its Business Is Yet to Catch Up
Sumitomo Pharma Co., Ltd. ( TSE:4506 ) shares have continued their recent momentum with a 36% gain in the last month...Analysis Article • Jul 06
Does Sumitomo Pharma (TSE:4506) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • Jun 15
Sumitomo Pharma Co., Ltd.'s (TSE:4506) 30% Share Price Surge Not Quite Adding Up
Sumitomo Pharma Co., Ltd. ( TSE:4506 ) shares have continued their recent momentum with a 30% gain in the last month...Analysis Article • May 20
We Believe Sumitomo Pharma's (TSE:4506) Earnings Are A Poor Guide For Its Profitability
Strong earnings weren't enough to please Sumitomo Pharma Co., Ltd.'s ( TSE:4506 ) shareholders over the last week. We...Analysis Article • May 15
Sumitomo Pharma Co., Ltd. Just Recorded A 72% EPS Beat: Here's What Analysts Are Forecasting Next
A week ago, Sumitomo Pharma Co., Ltd. ( TSE:4506 ) came out with a strong set of full-year numbers that could...Analysis Article • Apr 09
Why Investors Shouldn't Be Surprised By Sumitomo Pharma Co., Ltd.'s (TSE:4506) 26% Share Price Plunge
Sumitomo Pharma Co., Ltd. ( TSE:4506 ) shares have had a horrible month, losing 26% after a relatively good period...Analysis Article • Mar 19
Is Sumitomo Pharma (TSE:4506) Using Debt In A Risky Way?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • Feb 04
Sumitomo Pharma Co., Ltd. Just Recorded A 593% EPS Beat: Here's What Analysts Are Forecasting Next
Sumitomo Pharma Co., Ltd. ( TSE:4506 ) just released its quarterly report and things are looking bullish. Statutory...Analysis Article • Jan 11
Sentiment Still Eluding Sumitomo Pharma Co., Ltd. (TSE:4506)
You may think that with a price-to-sales (or "P/S") ratio of 0.6x Sumitomo Pharma Co., Ltd. ( TSE:4506 ) is a stock...Analysis Article • Nov 25
Sumitomo Pharma (TSE:4506) Has Debt But No Earnings; Should You Worry?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • Sep 12
Is There An Opportunity With Sumitomo Pharma Co., Ltd.'s (TSE:4506) 38% Undervaluation?
Key Insights The projected fair value for Sumitomo Pharma is JP¥909 based on 2 Stage Free Cash Flow to Equity Current...Analysis Article • Aug 16
There's No Escaping Sumitomo Pharma Co., Ltd.'s (TSE:4506) Muted Revenues Despite A 26% Share Price Rise
Sumitomo Pharma Co., Ltd. ( TSE:4506 ) shares have continued their recent momentum with a 26% gain in the last month...Analysis Article • Jun 26
A Piece Of The Puzzle Missing From Sumitomo Pharma Co., Ltd.'s (TSE:4506) 28% Share Price Climb
Those holding Sumitomo Pharma Co., Ltd. ( TSE:4506 ) shares would be relieved that the share price has rebounded 28% in...Analysis Article • May 13
Is Sumitomo Pharma Co., Ltd. (TSE:4506) Trading At A 34% Discount?
Key Insights Sumitomo Pharma's estimated fair value is JP¥628 based on 2 Stage Free Cash Flow to Equity Sumitomo Pharma...Analysis Article • Apr 17
Market Cool On Sumitomo Pharma Co., Ltd.'s (TSE:4506) Revenues
You may think that with a price-to-sales (or "P/S") ratio of 0.5x Sumitomo Pharma Co., Ltd. ( TSE:4506 ) is a stock...Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 3/31/2029 | 618,792 | 77,197 | 99,767 | 102,669 | 6 |
| 3/31/2028 | 615,088 | 99,621 | 107,033 | 104,694 | 7 |
| 3/31/2027 | 563,243 | 95,693 | 110,643 | 84,636 | 7 |
| 6/30/2026 | 474,787 | 112,656 | 58,577 | 64,464 | N/A |
| 3/31/2026 | 453,294 | 106,865 | 64,403 | 71,715 | N/A |
| 12/31/2025 | 453,395 | 110,092 | 46,013 | 53,277 | N/A |
| 9/30/2025 | 445,205 | 154,723 | 21,922 | 29,973 | N/A |
| 6/30/2025 | 416,159 | 18,903 | 30,261 | 41,361 | N/A |
| 3/31/2025 | 398,832 | 23,634 | 3,470 | 16,500 | N/A |
| 12/31/2024 | 372,713 | -176,042 | -21,405 | -5,670 | N/A |
| 9/30/2024 | 342,665 | -279,457 | -78,396 | -62,844 | N/A |
| 6/30/2024 | 329,547 | -260,167 | -151,893 | -136,785 | N/A |
| 3/31/2024 | 314,558 | -314,969 | -257,623 | -241,893 | N/A |
| 12/31/2023 | 330,307 | -173,718 | -289,603 | -275,326 | N/A |
| 9/30/2023 | 388,897 | -134,970 | -195,585 | -192,040 | N/A |
| 6/30/2023 | 471,354 | -144,485 | -132,356 | -131,413 | N/A |
| 3/31/2023 | 555,544 | -74,512 | 11,310 | 11,937 | N/A |
| 12/31/2022 | 588,228 | -8,448 | 78,665 | 78,709 | N/A |
| 9/30/2022 | 585,594 | 12,680 | 77,510 | 88,927 | N/A |
| 6/30/2022 | 588,715 | 82,719 | 62,735 | 77,233 | N/A |
| 3/31/2022 | 560,035 | 56,413 | 17,745 | 31,239 | N/A |
| 12/31/2021 | 553,262 | 32,321 | 23,680 | 36,782 | N/A |
| 9/30/2021 | 548,184 | 55,372 | 67,806 | 81,324 | N/A |
| 6/30/2021 | 513,291 | 42,762 | 90,302 | 102,279 | N/A |
| 3/31/2021 | 515,952 | 56,219 | 124,795 | 135,601 | N/A |
| 12/31/2020 | 520,477 | 67,031 | 105,325 | 117,235 | N/A |
| 9/30/2020 | 513,627 | 47,720 | 30,439 | 40,420 | N/A |
| 6/30/2020 | 499,105 | 52,309 | 26,399 | 38,398 | N/A |
| 3/31/2020 | 482,732 | 40,753 | N/A | 46,128 | N/A |
| 12/31/2019 | 469,413 | 52,637 | N/A | 66,333 | N/A |
| 9/30/2019 | 463,715 | 51,088 | N/A | 73,527 | N/A |
| 6/30/2019 | 460,840 | 40,083 | N/A | 65,450 | N/A |
| 3/31/2019 | 459,267 | 48,627 | N/A | 48,711 | N/A |
| 12/31/2018 | 449,588 | 42,826 | N/A | N/A | N/A |
| 9/30/2018 | 452,530 | 46,430 | N/A | 55,607 | N/A |
| 6/30/2018 | 466,452 | 54,285 | N/A | N/A | N/A |
| 3/31/2018 | 466,838 | 53,448 | N/A | 93,420 | N/A |
| 12/31/2017 | 470,252 | 50,011 | N/A | N/A | N/A |
| 9/30/2017 | 454,013 | 52,956 | N/A | 52,872 | N/A |
| 6/30/2017 | 424,447 | 35,035 | N/A | N/A | N/A |
| 3/31/2017 | 411,638 | 28,991 | N/A | 21,624 | N/A |
| 12/31/2016 | 404,181 | 30,923 | N/A | N/A | N/A |
| 9/30/2016 | 402,368 | 22,405 | N/A | 48,663 | N/A |
| 6/30/2016 | 408,566 | 27,122 | N/A | N/A | N/A |
| 3/31/2016 | 403,206 | 24,697 | N/A | 49,415 | N/A |
| 12/31/2015 | 396,763 | 19,799 | N/A | N/A | N/A |
| 9/30/2015 | 392,006 | 16,903 | N/A | 22,963 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 4506's earnings are forecast to decline over the next 3 years (-7.9% per year).
Earnings vs Market: 4506's earnings are forecast to decline over the next 3 years (-7.9% per year).
High Growth Earnings: 4506's earnings are forecast to decline over the next 3 years.
Revenue vs Market: 4506's revenue (5.8% per year) is forecast to grow slower than the JP market (6.4% per year).
High Growth Revenue: 4506's revenue (5.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 4506's Return on Equity is forecast to be low in 3 years time (13.4%).
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/22 00:22 |
| End of Day Share Price | 2026/09/18 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sumitomo Pharma Co., Ltd. is covered by 17 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Atsushi Seki | Barclays |
| Koichi Mamegano | BofA Global Research |
| Hidemaru Yamaguchi | Citigroup Inc |